Holen Sie sich die Stockscreener-App
19.79
5.77%
1.08
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BAX?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$18.71
Offen:
$18.67
24-Stunden-Volumen:
15.81M
Relative Volume:
1.76
Marktkapitalisierung:
$10.17B
Einnahmen:
$10.89B
Nettoeinkommen (Verlust:
$-241.00M
KGV:
-74.51
EPS:
-0.2656
Netto-Cashflow:
$340.00M
1W Leistung:
-8.93%
1M Leistung:
+0.71%
6M Leistung:
-17.92%
1J Leistung:
-35.37%
1-Tages-Spanne:
$18.61
$20.13
1-Wochen-Bereich:
$18.57
$22.41
52-Wochen-Spanne:
$17.40
$37.74
Baxter International Inc Stock (BAX) Company Profile
Firmenname
Baxter International Inc
Sektor
Telefon
(224) 948-2000
Adresse
ONE BAXTER PARKWAY, DEERFIELD, IL
Compare BAX vs ISRG, BDX, ALC, MDLN, RMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BAX
Baxter International Inc
|
19.79 | 9.62B | 10.89B | -241.00M | 340.00M | -0.2656 |
|
ISRG
Intuitive Surgical Inc
|
485.84 | 169.97B | 10.06B | 2.88B | 2.49B | 7.876 |
|
BDX
Becton Dickinson Co
|
175.89 | 50.58B | 21.92B | 1.76B | 2.63B | 6.1223 |
|
ALC
Alcon Inc
|
79.20 | 38.58B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
MDLN
Medline Inc
|
44.55 | 37.11B | 27.43B | 1.27B | 1.01B | 1.5829 |
|
RMD
Resmed Inc
|
252.55 | 35.80B | 5.40B | 1.49B | 1.78B | 10.12 |
Baxter International Inc Stock (BAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-31 | Herabstufung | Argus | Buy → Hold |
| 2025-08-04 | Herabstufung | Stifel | Buy → Hold |
| 2025-08-01 | Herabstufung | Goldman | Buy → Neutral |
| 2025-02-26 | Fortgesetzt | Goldman | Buy |
| 2025-02-24 | Hochstufung | Argus | Hold → Buy |
| 2025-02-20 | Fortgesetzt | Barclays | Overweight |
| 2024-07-15 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2024-05-30 | Eingeleitet | Goldman | Neutral |
| 2024-05-10 | Herabstufung | TD Cowen | Buy → Hold |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-03-29 | Eingeleitet | UBS | Neutral |
| 2023-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-01-05 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-12-19 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-12-15 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2022-12-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-06-24 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-04-04 | Herabstufung | Goldman | Neutral → Sell |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-02-18 | Bestätigt | KeyBanc Capital Markets | Overweight |
| 2022-02-18 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-18 | Bestätigt | Raymond James | Outperform |
| 2022-02-18 | Bestätigt | Stifel | Buy |
| 2022-02-18 | Bestätigt | UBS | Neutral |
| 2022-02-18 | Bestätigt | Wells Fargo | Overweight |
| 2022-02-11 | Eingeleitet | Goldman | Neutral |
| 2022-01-07 | Fortgesetzt | Citigroup | Buy |
| 2022-01-07 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-09-13 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-09-03 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2021-05-25 | Eingeleitet | Barclays | Equal Weight |
| 2021-01-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-01-06 | Herabstufung | UBS | Buy → Neutral |
| 2020-12-15 | Herabstufung | Goldman | Buy → Neutral |
| 2020-10-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-09-04 | Herabstufung | Argus | Buy → Hold |
| 2020-06-24 | Eingeleitet | Oppenheimer | Outperform |
| 2020-03-19 | Hochstufung | Stifel | Hold → Buy |
| 2020-03-18 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-03-05 | Eingeleitet | Citigroup | Neutral |
| 2020-02-13 | Eingeleitet | Goldman | Buy |
| 2020-01-02 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-12-17 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-26 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2019-04-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-01-02 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-01-02 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2018-11-02 | Hochstufung | Argus | Hold → Buy |
| 2018-10-16 | Eingeleitet | Barclays | Underweight |
| 2018-05-17 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-02-06 | Bestätigt | Citigroup | Neutral |
| 2018-01-03 | Eingeleitet | Evercore ISI | Outperform |
| 2018-01-03 | Hochstufung | Raymond James | Mkt Perform → Outperform |
Alle ansehen
Baxter International Inc Aktie (BAX) Neueste Nachrichten
Baxter International Inc.: How a 90-Year Medtech Veteran Is Rebuilding Its Product Playbook - AD HOC NEWS
The Truth About Baxter International Inc.: Hidden Healthcare Giant or Total Snooze Stock? - AD HOC NEWS
Baxter lays off 90 employees from hurricane-hit unit - Medical Buyer
Baxter International Inc. stock outperforms competitors on strong trading day - MarketWatch
BAX Q4 Deep Dive: Mixed Segment Performance and Margin Pressures Shape Outlook - Finviz
Looking Into Baxter International Inc's Recent Short Interest - Benzinga
Barclays Lowers Price Target for Baxter Intl (BAX) While Maintai - GuruFocus
Baxter sales up 8% to USD 2.97B in Q4 2025 - Medical Buyer
Baxter International Inc. (NYSE:BAX) Q4 2025 Earnings Call Transcript - Insider Monkey
Baxter International Inc. (NYSE:BAX) Q4 2025 earnings call transcript - MSN
Baxter's new CEO mired in damage control before he can address long-term problems - Crain's Chicago Business
Baxter International Inc. stock underperforms Thursday when compared to competitors - MSN
Baxter Stock (-16%): Profit Guidance Collapse Triggers De-Risking - Trefis
Decoding Baxter International Inc (BAX): A Strategic SWOT Insigh - GuruFocus
Baxter International Is Quietly Going Off – But Is BAX Stock Really Worth Your Money? - AD HOC NEWS
Baxter International (BAX) Q4 2025 Sales Exceed Expectations, EPS Falls Short - GuruFocus
Baxter is the S&P 500’s worst performer today. Earnings were brutal. - MSN
Baxter International Earnings Call: Growth Meets Margin Squeeze - TipRanks
BAXTER INTERNATIONAL INC SEC 10-K Report - TradingView
Baxter International Inc (BAX) Q4 2025 Earnings Call Highlights: Strong Sales Growth Amidst Margin Pressures - GuruFocus
Baxter stock dives on Q4 EPS miss, company introduces new operating model - massdevice.com
Baxter International: Debt, Margin Pressure, Dreadful FY26 Guidance (Downgrade) (NYSE:BAX) - Seeking Alpha
Baxter shares tumble 16% on weak earnings - breakingthenews.net
Baxter International Stock Falls Sharply. Earnings Were Brutal. - Barron's
Baxter International Q4 Earnings Call Highlights - Yahoo Finance
Key facts: Baxter International appoints McDonnell; reports Q4 loss - TradingView
Why Baxter International Stock Was Tumbling Today - AOL.com
Baxter Turnaround Efforts Continue, but Outcome Remains Uncertain - Morningstar
Baxter annual profit forecast disappoints as key product troubles mount - marketscreener.com
Why Baxter International Stock Was Tumbling Today - The Motley Fool
Baxter forecast 2026 profit below estimates - marketscreener.com
Baxter (BAX) Q4 2025 Earnings Call Transcript - The Globe and Mail
Baxter Shares Tank As 2026 Profit Guidance Falls Below Expectations - Bitget
Baxter Shares Tank, 2026 Profit Guidance Lower Than ExpectedBaxter Intl (NYSE:BAX) - Benzinga
BAX Stock Falls Following Q4 Earnings Miss, Margins Contract - The Globe and Mail
Baxter Faces Legal Claims Amid Financial Uncertainty - StocksToTrade
Baxter CEO: ‘We need to get better’ - Modern Healthcare News
Baxter International Faces Potential Legal Claims Amid Stock Concerns - timothysykes.com
Baxter International Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Earnings call transcript: Baxter’s Q4 2025 results miss EPS forecast, stock drops By Investing.com - Investing.com India
Baxter slips following Q4 bottom line miss, weak 2026 EPS guidance - MSN
Baxter Q4 2025 slides: Revenue grows 8% but margins compress, EPS misses target By Investing.com - Investing.com India
Baxter International (BAX) Sees Market Activity Rise - GuruFocus
Legal Concerns Loom Over Baxter Amid Fiduciary Duty Accusations - StocksToTrade
Earnings call transcript: Baxter’s Q4 2025 results miss EPS forecast, stock drops - Investing.com
Baxter (BAX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance Australia
Baxter Shares Plunge on Dismal Financial Outlook - AD HOC NEWS
Baxter International (BAX) Q4 Earnings Lag Estimates - Yahoo Finance
Baxter International Inc (NYSE:BAX) Stock Plummets on Q4 Earnings Miss and Weak 2026 Outlook - ChartMill
Baxter: Q4 Earnings Snapshot - kens5.com
Baxter: Fourth Quarter Financial Overview - Bitget
Finanzdaten der Baxter International Inc-Aktie (BAX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.53%
1.58%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):